OverviewSuggest Edit

Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop medicines for chronic neurologic disorders, which is built upon its understanding of time-dependent biologic processes responsible for specific disease activities and drug response.

Adamas Pharmaceuticals' lead product candidate, ADS-5102, is a high-dose amantadine therapy in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. It is also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial-onset seizures in patients with epilepsy.

Additionally, Adamas' licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® extended-release capsules, and Namzaric® capsules, are currently marketed by Allergan.

TypePublic
Founded2002
HQEmeryville, US
Websiteadamaspharma.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Sep 2019)134(-4%)
Job Openings7
Revenue (FY, 2018)$34 M(+5863%)
Share Price (Nov 2019)$5.5

Key People/Management at Adamas Pharmaceuticals

Gregory Went

Gregory Went

Chief Executive Officer & Chairman
Alf Merriweather

Alf Merriweather

CFO
David Mahoney

David Mahoney

Director
Show more

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville
Emeryville, US (HQ)
1900 Powell St #750
Show all (1)

Adamas Pharmaceuticals Financials and Metrics

Adamas Pharmaceuticals Revenue

Adamas Pharmaceuticals's revenue was reported to be $34.05 m in FY, 2018
USD

Revenue (Q3, 2019)

13.9m

Market capitalization (15-Nov-2019)

154.3m

Closing stock price (15-Nov-2019)

5.5

Cash (30-Sep-2019)

72.0m

EV

208.2m
Adamas Pharmaceuticals's current market capitalization is $154.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

55.8m1.9m572.0k571.0k34.0m

Revenue growth, %

(97%)(70%)

Cost of goods sold

17.0k633.0k

Gross profit

554.0k33.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

176.0k25.2m215.0k226.0k398.0k768.0k175.0k222.0k138.0k2.0k1.0k2.6m7.6m10.6m13.9m

Cost of goods sold

25.0k73.0k100.0k413.0k685.0k

Gross profit

2.5m7.5m10.5m

Gross profit Margin, %

99%99%99%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

61.4m33.1m23.7m91.3m56.6m

Accounts Receivable

524.0k1.3m794.0k367.0k5.5m

Prepaid Expenses

3.7m6.9m

Inventories

645.0k5.1m2.5m1.7m5.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

79.8m144.6m137.5m29.2m37.9m37.1m98.4m109.3m9.8m20.9m33.6m22.1m50.9m40.6m56.8m58.9m62.7m72.0m

Accounts Receivable

251.0k218.0k120.0k485.0k361.0k936.0k461.0k860.0k769.0k1.7m34.0k3.0k1.6m3.4m5.3m7.5m6.4m5.5m

Prepaid Expenses

542.0k956.0k1.3m540.0k1.6m1.1m5.8m6.3m7.4m1.5m1.8m2.8m3.5m4.8m4.4m6.5m6.3m6.4m

Inventories

425.0k2.5m3.8m5.2m5.2m5.7m5.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

10.2m(51.8m)(60.1m)(89.5m)(131.0m)

Depreciation and Amortization

155.0k435.0k808.0k1.2m

Inventories

(97.8m)(153.7m)2.1m(1.6m)(3.3m)

Accounts Payable

1.5m(788.0k)502.0k333.0k2.8m
USDY, 2019

EV/CFO

-3.3 x

Revenue/Employee

104.0k

Debt/Equity

6.4 x

Debt/Assets

0.7 x

Financial Leverage

9.1 x
Show all financial metrics

Adamas Pharmaceuticals Online and Social Media Presence

Embed Graph

Adamas Pharmaceuticals News and Updates

Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role

Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as its Chief…

ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.'s January 24, 2018 Secondary Public Offering To Contact The Firm

NEW YORK, May 24, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS). If you purchased Adamas stock pursuant to the Company's January 24, 2018...

Adamas Pharmaceuticals Blogs

Adamas Reports Third Quarter 2019 Financial Results

- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019 EMERYVILLE, Calif., Nov.

Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

EMERYVILLE, Calif. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019 , after market close. Subsequently, Adamas’ management team will host a conference call

Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

EMERYVILLE, Calif. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane , the Company’s Chief Executive Officer, is

Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

EMERYVILLE, Calif. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI ® (amantadine)

Adamas Reports Second Quarter 2019 Financial Results

Adamas Reports Second Quarter 2019 Financial Results Content Import Thu, 08/08/2019 - 16:02 Adamas Reports Second Quarter 2019 Financial Results Aug 8, 2019 This release is a backfill from a News Wire Earnings - Second quarter GOCOVR…

Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019 Content Import Tue, 07/23/2019 - 16:07 Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019 Jul 23, 2019 This re…
Show more

Adamas Pharmaceuticals Frequently Asked Questions

  • When was Adamas Pharmaceuticals founded?

    Adamas Pharmaceuticals was founded in 2002.

  • Who are Adamas Pharmaceuticals key executives?

    Adamas Pharmaceuticals's key executives are Gregory Went, Alf Merriweather and David Mahoney.

  • How many employees does Adamas Pharmaceuticals have?

    Adamas Pharmaceuticals has 134 employees.

  • What is Adamas Pharmaceuticals revenue?

    Latest Adamas Pharmaceuticals annual revenue is $34 m.

  • What is Adamas Pharmaceuticals revenue per employee?

    Latest Adamas Pharmaceuticals revenue per employee is $254.1 k.

  • Who are Adamas Pharmaceuticals competitors?

    Competitors of Adamas Pharmaceuticals include Opiant Pharmaceuticals, Mylan and E-Therapeutics.

  • Where is Adamas Pharmaceuticals headquarters?

    Adamas Pharmaceuticals headquarters is located at 1900 Powell St #750, Emeryville.

  • Where are Adamas Pharmaceuticals offices?

    Adamas Pharmaceuticals has an office in Emeryville.

  • How many offices does Adamas Pharmaceuticals have?

    Adamas Pharmaceuticals has 1 office.